Browse EGR1

Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm
Domain PF11914 Domain of unknown function (DUF3432)
PF11928 Domain of unknown function (DUF3446)
Function

Transcriptional regulator (PubMed:20121949). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'(EGR-site) in the promoter region of target genes (By similarity). Binds double-stranded target DNA, irrespective of the cytosine methylation status (PubMed:25258363, PubMed:25999311). Regulates the transcription of numerous target genes, and thereby plays an important role in regulating the response to growth factors, DNA damage, and ischemia. Plays a role in the regulation of cell survival, proliferation and cell death. Activates expression of p53/TP53 and TGFB1, and thereby helps prevent tumor formation. Required for normal progress through mitosis and normal proliferation of hepatocytes after partial hepatectomy. Mediates responses to ischemia and hypoxia; regulates the expression of proteins such as IL1B and CXCL2 that are involved in inflammatory processes and development of tissue damage after ischemia. Regulates biosynthesis of luteinizing hormone (LHB) in the pituitary (By similarity).

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001666 response to hypoxia
GO:0001819 positive regulation of cytokine production
GO:0001822 kidney development
GO:0002521 leukocyte differentiation
GO:0002931 response to ischemia
GO:0006694 steroid biosynthetic process
GO:0006700 C21-steroid hormone biosynthetic process
GO:0006701 progesterone biosynthetic process
GO:0007159 leukocyte cell-cell adhesion
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0008202 steroid metabolic process
GO:0008207 C21-steroid hormone metabolic process
GO:0009314 response to radiation
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0010565 regulation of cellular ketone metabolic process
GO:0010566 regulation of ketone biosynthetic process
GO:0010817 regulation of hormone levels
GO:0014706 striated muscle tissue development
GO:0016055 Wnt signaling pathway
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0019216 regulation of lipid metabolic process
GO:0019218 regulation of steroid metabolic process
GO:0030098 lymphocyte differentiation
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030217 T cell differentiation
GO:0030509 BMP signaling pathway
GO:0032350 regulation of hormone metabolic process
GO:0032352 positive regulation of hormone metabolic process
GO:0032602 chemokine production
GO:0032611 interleukin-1 beta production
GO:0032612 interleukin-1 production
GO:0032642 regulation of chemokine production
GO:0032651 regulation of interleukin-1 beta production
GO:0032652 regulation of interleukin-1 production
GO:0032722 positive regulation of chemokine production
GO:0032731 positive regulation of interleukin-1 beta production
GO:0032732 positive regulation of interleukin-1 production
GO:0032835 glomerulus development
GO:0032868 response to insulin
GO:0033233 regulation of protein sumoylation
GO:0034284 response to monosaccharide
GO:0034340 response to type I interferon
GO:0034754 cellular hormone metabolic process
GO:0035914 skeletal muscle cell differentiation
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0042033 chemokine biosynthetic process
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042110 T cell activation
GO:0042180 cellular ketone metabolic process
GO:0042181 ketone biosynthetic process
GO:0042222 interleukin-1 biosynthetic process
GO:0042445 hormone metabolic process
GO:0042446 hormone biosynthetic process
GO:0042448 progesterone metabolic process
GO:0042698 ovulation cycle
GO:0043434 response to peptide hormone
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress
GO:0043620 regulation of DNA-templated transcription in response to stress
GO:0044283 small molecule biosynthetic process
GO:0044849 estrous cycle
GO:0045073 regulation of chemokine biosynthetic process
GO:0045080 positive regulation of chemokine biosynthetic process
GO:0045360 regulation of interleukin-1 biosynthetic process
GO:0045362 positive regulation of interleukin-1 biosynthetic process
GO:0046885 regulation of hormone biosynthetic process
GO:0046886 positive regulation of hormone biosynthetic process
GO:0046890 regulation of lipid biosynthetic process
GO:0048511 rhythmic process
GO:0050720 interleukin-1 beta biosynthetic process
GO:0050722 regulation of interleukin-1 beta biosynthetic process
GO:0050725 positive regulation of interleukin-1 beta biosynthetic process
GO:0050755 chemokine metabolic process
GO:0050810 regulation of steroid biosynthetic process
GO:0060070 canonical Wnt signaling pathway
GO:0060337 type I interferon signaling pathway
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061418 regulation of transcription from RNA polymerase II promoter in response to hypoxia
GO:0061437 renal system vasculature development
GO:0061440 kidney vasculature development
GO:0061448 connective tissue development
GO:0070482 response to oxygen levels
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070498 interleukin-1-mediated signaling pathway
GO:0070555 response to interleukin-1
GO:0071214 cellular response to abiotic stimulus
GO:0071347 cellular response to interleukin-1
GO:0071357 cellular response to type I interferon
GO:0071417 cellular response to organonitrogen compound
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071478 cellular response to radiation
GO:0071479 cellular response to ionizing radiation
GO:0071480 cellular response to gamma radiation
GO:0071503 response to heparin
GO:0071504 cellular response to heparin
GO:0071505 response to mycophenolic acid
GO:0071506 cellular response to mycophenolic acid
GO:0071593 lymphocyte aggregation
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072012 glomerulus vasculature development
GO:0072109 glomerular mesangium development
GO:0072110 glomerular mesangial cell proliferation
GO:0072111 cell proliferation involved in kidney development
GO:0072124 regulation of glomerular mesangial cell proliferation
GO:0072126 positive regulation of glomerular mesangial cell proliferation
GO:0072203 cell proliferation involved in metanephros development
GO:0072210 metanephric nephron development
GO:0072215 regulation of metanephros development
GO:0072216 positive regulation of metanephros development
GO:0072223 metanephric glomerular mesangium development
GO:0072224 metanephric glomerulus development
GO:0072239 metanephric glomerulus vasculature development
GO:0072262 metanephric glomerular mesangial cell proliferation involved in metanephros development
GO:0072298 regulation of metanephric glomerulus development
GO:0072300 positive regulation of metanephric glomerulus development
GO:0072301 regulation of metanephric glomerular mesangial cell proliferation
GO:0072303 positive regulation of glomerular metanephric mesangial cell proliferation
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090183 regulation of kidney development
GO:0090184 positive regulation of kidney development
GO:0090192 regulation of glomerulus development
GO:0090193 positive regulation of glomerulus development
GO:0098758 response to interleukin-8
GO:0098759 cellular response to interleukin-8
GO:0198738 cell-cell signaling by wnt
GO:1901342 regulation of vasculature development
GO:1901652 response to peptide
GO:1901722 regulation of cell proliferation involved in kidney development
GO:1901724 positive regulation of cell proliferation involved in kidney development
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1904018 positive regulation of vasculature development
GO:2000182 regulation of progesterone biosynthetic process
Molecular Function GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0010385 double-stranded methylated DNA binding
GO:0035035 histone acetyltransferase binding
GO:0044729 hemi-methylated DNA-binding
GO:1990841 promoter-specific chromatin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EGR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between EGR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23312906Glioma; MesotheliomaPromote immunityIn two non epithelial cancers (glioma and mesothelioma), we found that the epigenetic regulation of the NY-ESO1 gene requires the sequential recruitment of the HDAC1-mSin3a-NCOR, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a complexes.The NY-ESO1 gene is a cancer/testis antigen considered to be suitable target for the immunotherapy of human malignancies.
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EGR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EGR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2340.705
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.30.615
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5590.746
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3940.656
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2130.948
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6130.889
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2580.643
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.6490.696
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2830.867
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7670.579
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.4230.182
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5860.00479
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EGR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EGR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EGR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EGR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EGR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EGR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EGR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEGR1
Nameearly growth response 1
Aliases TIS8; G0S30; NGFI-A; KROX-24; ZIF-268; AT225; nerve growth factor-induced protein A; transcription factor ET ......
Chromosomal Location5q23-q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EGR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.